Healthcare
Live Price
Offline$4.15
+5.87% today
1Y Change
+149.35%
Window
Jun 25, 2025 โ Jun 16, 2026
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
C4 Therapeutics Inc (CCCC) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $4.15 and up 149.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +1.0%, EPS growth of +16.4%, a dividend yield of 0.0%. What stands out right now is revenue +1.0%, EPS +16.4%, free cash flow -52.0% with operating margin -320.5% and ROIC -34.7%. Valuation sits in the middle of the pack at price/sales 6.8. Stock Foundry combines CCCC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.0% vs +7.6% peer median
Operating Margin
Below sector median
-320.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.0% and EPS at +16.4%, with operating margin around -320.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +12.5% over the next 5 trading days and finished higher after 3 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +1.7% | +25.6% | +42.3% |
2026 Feb 26, 2026 | +41.9% | -2.9% | +9.0% | -5.8% |
2025 Nov 6, 2025 | +6.4% | -1.7% | +2.9% | +12.2% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CCCC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CCCC Max Drawdown
-52.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CCCC and SPY.
Company Overview
C4 Therapeutics Inc
NASDAQ
C4 Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates that degrade disease-causing proteins through targeted protein degradation science. Its lead product candidate, Cemsidomide, is an orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 proteins, currently in Phase 1/2 clinical trials for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also advancing CFT1946, an orally bioavailable BiDAC degrader for BRAF V600 mutants in Phase 1/2 trials for melanoma, colorectal cancer, and other solid tumors, as well as CFT8919, a mutant-selective BiDAC degrader of epidermal growth factor receptor with L858R mutation for non-small cell lung cancer. C4 Therapeutics Inc. maintains strategic collaborations with partners such as Biogen, Roche, Merck KGaA, and others to expand its discovery and development efforts. Founded in 2015 and headquartered in Watertown, Massachusetts, it plays a key role in oncology by pioneering degraders that offer potentially improved efficacy and tolerability over traditional inhibitors.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.